Day One Projects 53% Growth in OJEMDA Revenue for 2026—Strong Momentum and Pipeline Expansion Signal Confidence
2025 Revenue Surges 172%, Setting Up Ambitious 2026 Targets
Day One Biopharmaceuticals is projecting robust growth as it heads into 2026. The company has announced preliminary 2025 OJEMDA net product revenue of $155.4 million, reflecting a striking 172% year-over-year increase. Looking to the next year, Day One is providing a revenue guidance range of $225 million to $250 million for OJEMDA in the U.S.—a midpoint climb of 53% over 2025. This momentum comes as Day One prepares to update investors at the J.P. Morgan Healthcare Conference.
Prescription Uptake and Strategic Expansion Drive Growth
OJEMDA’s commercial performance in 2025 was bolstered by prescription volumes rising to 1,394 in the fourth quarter alone, with Q4 net product revenue hitting $52.8 million (37% higher than Q3). The company credits this growth to increased demand and strategic commercial execution, including efforts to position OJEMDA as the standard of care for second-line pediatric low-grade glioma (pLGG).
Looking ahead, Day One aims to extend OJEMDA’s reach beyond the U.S. through global partnerships, accelerate new patient starts, and increase treatment persistence. The company will also complete enrollment in a pivotal Phase 3 trial (FIREFLY-2) and anticipates key clinical readouts in 2027, with an eye toward potential approval in 2028.
| Year | OJEMDA Net Product Revenue ($M) | YoY Growth (%) | Prescription Volume (Q4) |
|---|---|---|---|
| 2024 | 57.17 | — | — |
| 2025 | 155.40 | 172 | 1,394 |
| 2026 (Guidance) | 225–250 | 53 (midpoint) | — |
Cash Reserves and Pipeline Bolster Long-Term Outlook
Day One ended 2025 with approximately $441.1 million in cash and short-term investments (pre-Mersana acquisition), providing solid backing for continued investment in internal programs and external growth. The recent acquisition of Mersana Therapeutics brings an innovative antibody drug conjugate, Emi-Le, into the pipeline, further diversifying Day One’s clinical development efforts. The company expects to release initial Phase 1 data for both Emi-Le and the PTK7-targeted DAY301 program in 2026.
Milestones Ahead: What to Watch in 2026
Investors should mark the following milestones:
- Completion of OJEMDA Phase 3 trial enrollment in first-half 2026
- Initial clinical data for Emi-Le by mid-2026
- Early data for DAY301 in the second half of 2026
- Corporate updates and market expansion initiatives around OJEMDA
These milestones, combined with robust guidance and significant cash reserves, suggest Day One is positioned to build on its 2025 momentum.
Takeaway: Positioned for Growth but Monitoring Execution Risks
Day One’s preliminary results and guidance paint the portrait of a biopharma firm seizing opportunity both commercially and clinically. While forward-looking statements inherently bring risk—especially with integration challenges from acquisitions and ongoing clinical trials—the rapid uptake of OJEMDA and a focus on new indications provide solid reasons for optimism. Investors may want to watch upcoming data releases and milestones closely as the company continues to execute on its growth strategy.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI